Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Realign Business Groups to Focus on Human, Environmental Health

NEW YORK (GenomeWeb News) – PerkinElmer announced after market close today that it will realign its business units as of Jan. 1, 2009, to focus on human and environmental health.
PerkinElmer’s operations are currently organized into two main divisions: Life and Analytical Sciences and Optoelectronics. Under the new model, the company’s operations will be split between two new businesses: Human Health and Environmental Health.
The Human Health business will develop diagnostics, tools, and applications for biomedical research and drug discovery. This business will include the company’s Genetic Screening, Bio-discovery, and Medical Imaging operating units. Robert Friel, PerkinElmer’s president and CEO, will lead the Human Health business on an interim basis.
The Environmental Health business will be focused on product safety and energy efficiency. It will include the company’s Analytical Sciences, Laboratory Services, and Detection and Illumination (formerly known as Sensors and Specialty Lighting) operating units. John Roush, who currently leads the company’s Optoelectronics business, will lead this division.
In line with the restructuring, PerkinElmer said it has placed “a portion” of its specialty lighting business, which includes xenon flashtubes, ceramic xenon light sources, intense pulsed light, laser pump sources, and LEDs, under strategic review.
The company said that the businesses under review are expected to generate around $90 million in revenue for 2008.
PerkinElmer does not break out revenues for its product lines, but the Optoelectronics segment that houses the specialty lighting business generated total sales of $460.1 million in fiscal 2007, while the company's total revenues for the year were $1.79 billion.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.